Evidence map›Paper›PMID 20962021›Full record

Trial reportThe Journal of clinical endocrinology and metabolism2011

Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline.

Kenneth C Copeland, Philip Zeitler, Mitchell Geffner, Cindy Guandalini, Janine Higgins, Kathryn Hirst, Francine R Kaufman, Barbara Linder, Santica Marcovina, Paul McGuigan and 4 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of clinical endocrinology and metabolism, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00081328. Cited by 225 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
225citing papers in PubMed, 5 pooled it
11.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00081328 phase3completed

Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Clinical Trial

Ran2004Enrolled699Registered outcomes11Posted comparisons0ConditionsDiabetes Mellitus, Type IIArmsLifestyle Program, Metformin, Rosiglitazone
PMID 22540912PMID 27803118PMID 24450390PMID 29246363PMID 31167889PMID 29532078PMID 27352955PMID 22332798PMID 31685489PMID 23704674PMID 26537182PMID 29398050other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

225 citing papers in PubMed, 5 syntheses or guidelines pooled it, 458 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Drug interventions for the treatment of obesity in children and adolescents.The Cochrane database of systematic reviews · 2016
    Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

165 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 1 country.

Kenneth C CopelandUniversity of Oklahoma College of Medicine, 1200 North Phillips, Suite 4500, Oklahoma City, Oklahoma 73104. kenneth-copeland@ouhsc.edu.
Philip Zeitler
Mitchell Geffner
Cindy Guandalini
Janine Higgins
Kathryn Hirst
Francine R Kaufman
Barbara Linder
Santica Marcovina
Paul McGuigan
Laura Pyle
William Tamborlane
Steven Willi
TODAY Study Group
George Washington University · USUniversity of Colorado Denver · USYale University · USCase Western Reserve University · USChildren's Hospital of Los Angeles · USNational Institutes of Health · USUniversity of Oklahoma · USUniversity of Pennsylvania · USUniversity of Washington · US

Funding

Statistics Center for Pediatric Type 2 Diabetes TherapyU01DK061230 · GEORGE WASHINGTON UNIVERSITY · 2001 to 2005
$69.5M
ZOPOLRESTAT IN NORMOTENSIVE, TYPE 1 DIA WITH INCIPIENT NEPHROPATHYM01RR000043 · UNIVERSITY OF SOUTHERN CALIFORNIA · 1985 to 2005
$43.4M
ZD6416 Analgesic--Painful Distal Symmetrical PolyneuropaM01RR001066 · MASSACHUSETTS GENERAL HOSPITAL · 1985 to 2005
$26.1M
ZIPRASIDONE IN TOURETTES SYNDROME, OBSESSIVE COMPULSIVE &PERVASIVE DEV. DISORDERM01RR000125 · YALE UNIVERSITY · 1985 to 2005
$20.7M
XANAX PET SCAN/IV LACTATE PANIC STUDYM01RR000036 · WASHINGTON UNIVERSITY · 1985 to 2005
$20.4M
ZORVIRAX ORAL SUSPENSION FOR SEVERE CHILDHOOD HERPES VIRUS INFECTIONSM01RR000069 · UNIVERSITY OF COLORADO DENVER · 1985 to 2005
$15.4M
Trt. of Primary Hyperaldosteronism w/ACE Inhibitors &Angiotension Rec. BlockersM01RR014467 · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · 2001 to 2005
$7.3M
WATER PRECAUTIONS AND TYMPANOSTOMY TUBESM01RR000084 · CHILDREN'S HOSP PITTSBURGH/UPMC HLTH SYS · 1985 to 2005
$5.2M
Management of Pediatric Type 2 Diabetes MellitusU01DK061239 · CHILDRENS HOSPITAL OF PHILADELPHIA · 2001 to 2005
$4.6M
Multi-Center Study of the Treatment of T2DM in YouthU01DK061212 · YALE UNIVERSITY · 2001 to 2005
$3.9M
Type 2 Diabetes in Youth: Beta Cell PreservationU01DK061254 · CHILDREN'S HOSP PITTSBURGH/UPMC HLTH SYS · 2001 to 2005
$3.6M
Treatment Alternatives in Pediatric Type 2 DiabetesU01DK061242 · UNIVERSITY OF COLORADO DENVER · 2001 to 2005
$3.5M
NCRR NIH HHS M01 RR000036NCRR NIH HHS M01 RR000043NCRR NIH HHS M01 RR000069NCRR NIH HHS M01 RR000084NCRR NIH HHS M01 RR000125NCRR NIH HHS M01-RR00036NCRR NIH HHS M01-RR00043-45NCRR NIH HHS M01-RR00069NCRR NIH HHS M01-RR00084NCRR NIH HHS M01 RR001066NCRR NIH HHS M01-RR00125NCRR NIH HHS M01-RR01066NCRR NIH HHS M01 RR014467NCRR NIH HHS M01-RR14467NCRR NIH HHS UL1 RR024134NCRR NIH HHS UL1-RR024134NCRR NIH HHS UL1 RR024139NCRR NIH HHS UL1-RR024139NCRR NIH HHS UL1 RR024153NCRR NIH HHS UL1-RR024153NCRR NIH HHS UL1 RR024989NCRR NIH HHS UL1-RR024989NCRR NIH HHS UL1 RR024992NCRR NIH HHS UL1-RR024992NCRR NIH HHS UL1 RR025758NCRR NIH HHS UL1-RR025758NCRR NIH HHS UL1 RR025780NCRR NIH HHS UL1-RR025780NIDDK NIH HHS U01 DK061212NIDDK NIH HHS U01 DK061230NIDDK NIH HHS U01 DK061239NIDDK NIH HHS U01 DK061242NIDDK NIH HHS U01 DK061254NIDDK NIH HHS U01-DK61212NIDDK NIH HHS U01-DK61230NIDDK NIH HHS U01-DK61239NIDDK NIH HHS U01-DK61242NIDDK NIH HHS U01-DK61254
6 · The paper itself

Abstract

contextThe Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) cohort represents the largest and best-characterized national sample of American youth with recent-onset type 2 diabetes.

objectiveThe objective of the study was to describe the baseline characteristics of participants in the TODAY randomized clinical trial.

designParticipants were recruited over 4 yr at 15 clinical centers in the United States (n = 704) and enrolled, randomized, treated, and followed up 2-6 yr.

settingThe study was conducted at pediatric diabetes care clinics and practices.

participantsEligible participants were aged 10-17 yr inclusive, diagnosed with type 2 diabetes for less than 2 yr and had a body mass index at the 85th percentile or greater.

interventionsAfter baseline data collection, participants were randomized to one of the following groups: 1) metformin alone, 2) metformin plus rosiglitazone, or 3) metformin plus a lifestyle program of weight management.

main outcome measuresBaseline data presented include demographics, clinical/medical history, biochemical measurements, and clinical and biochemical abnormalities.

resultsAt baseline the cohort included the following: 64.9% were female; mean age was 14.0 yr; mean diabetes duration was 7.8 months; mean body mass index Z-score was 2.15; 89.4% had a family history of diabetes; 41.1% were Hispanic, 31.5% were non-Hispanic black; 38.8% were living with both biological parents; 41.5% had a household annual income of less than $25,000; 26.3% had a highest education level of parent/guardian less than a high school degree; 26.3% had a blood pressure at the 90th percentile or greater; 13.6% had a blood pressure at the 95th percentile or greater; 13.0% had microalbuminuria; 79.8% had a low high-density lipoprotein level; and 10.2% had high triglycerides.

conclusionsThe TODAY cohort is predominantly from racial/ethnic minority groups, with low socioeconomic status and a family history of diabetes. Clinical and biochemical abnormalities and comorbidities are prevalent within 2 yr of diagnosis. These findings contribute greatly to our understanding of American youth with type 2 diabetes.

Indexed as

AdolescentBlood GlucoseBody Mass IndexChildCohort StudiesDiabetes Mellitus, Type 2FemaleHumansInsulinLipidsMaleObesityPhysical ExaminationQuality of LifeBlood GlucoseInsulinLipids

Identifiers

PMID20962021
PMCPMC3038479
OpenAlexW2034098851

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.